Botanical And Plant Derived Drug Market By Therapeutic Applications (Hormone Diseases, Pain And Central Nervous System Disorders), By Types Of Plant Drugs (Steroids, Phenols, Terpenes, Glycosides), Industry Size, Growth, Share And Forecast To 2022
Key Findings
The global botanical and plant derived drug market is expected to grow at the CAGR of 6.8% during 2015-2022. Botanical and plant derived drug market has wide applications in medical field. Rising prevalence of chronic diseases has made a significant impact in the growth of botanical and plant derived drug market. Plant derived drug are comparatively low in price as compared to other chemical derived drugs. Improved sociological and technological advancements are the key factors that are driving the growth of this market. Moreover, increasing number of FDA approvals for botanical and plant derived drugs and their applications are acting as an opportunity for the growth of plant derived drugs market. Although there are many factors driving the market yet there are some challenges faced by the market such as availability of alternatives and lack of awareness related to advantages of botanical and plant derived drugs.
Market Segment Insight
The market is majorly segmented on the basis of therapeutic applications and plant drug types. On the basis of therapeutic applications the market is further segregated into hormone diseases, infectious diseases, pain & central nervous system disorders, cardiovascular & metabolic diseases and respiratory & oncology diseases treatment. Botanical and plant derived drug are further segmented on the basis of types of plant drugs into steroids, phenols, terpenes and glycosides.
Regional Insight
Based on geography the market is segmented into North America, Europe, APAC, Middle East & Africa and Latin America. Europe & North America dominates the global botanical and plant derived drug owing to increasing awareness of botanical and plant derived drugs and rising prevalence of diseases. Asia Pacific is anticipated to grow significantly over the forecasted period owing to advancements in medical industry in the region. India and China are anticipated to witness significant growth rate due to growing population in the region and rising prevalence of chronic diseases.
Competitive Insights
Some of the major market players are Abott Laboratories, Curapharm Bayer Healthcare, Bionova, and Bristol Myers. Technological upgradations, mergers & acquisitions and agreements & collaborations are the key strategies adopted by the market players to sustain in the market.
CHAP 1. METHODOLOGY & SCOPE 11
1.1. RESEARCH METHODOLOGY 11
1.2. RESEARCH SCOPE & ASSUMPTIONS 11
1.3. LIST OF DATA SOURCES 11
CHAP 2. EXECUTIVE SUMMARY 12
2.1. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET SUMMARY & KEY BUYING CRITERIA 12
2.2. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET OUTLOOK 12
2.3. MARKET SEGMENTATION ANALYSIS 12
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 12
2.5. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET VALUE CHAIN ANALYSIS 12
2.6. VENDOR LANDSCAPE 12
CHAP 3. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET 13
3.1. MARKET DRIVER ANALYSIS 13
3.1.1. RISING USAGE OF THESE DRUGS IN VARIOUS MEDICINES 13
3.1.2. INCREASING PREVALENCE OF CHRONIC DISEASES 13
3.1.3. TECHNOLOGICAL ADVANCEMENT IN PRODUCTION PROCEDURE 13
3.1.4. COMPARATIVELY LOW PRICE 13
3.2. MARKET RESTRAINT ANALYSIS 13
3.2.1. STRINGENT LAWS AND REGULATIONS 13
3.2.2. LOW ACCEPTANCE FOR LETHAL DISEASES 13
3.3. KEY OPPORTUNITIES 13
3.3.1. ENHANCED APPLICATIONS 13
3.3.2. INCREASING NUMBER OF FDA APPROVALS 13
3.4. CHALLENGES 13
3.4.1. AVALABILITY OF ALTERNATE SUBSTITUTES 13
3.4.2. LACK OF AWARENESS 13
CHAP 4. INDUSTRY ANALYSIS 14
4.1. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET– PORTER’S FIVE FORCE MODEL 14
4.2. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET– PESTEL ANALYSIS 14
4.3. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET– GAP ANALYSIS 14
CHAP 5. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY THERAPEUTIC APPLICATIONS, 2012-2022 ($ BILLION) 15
5.1. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY HORMONE DISEASES, 2012-2022 ($ BILLION) 15
5.2. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY PAIN AND CENTRAL NERVOUS SYSTEM DISORDERS, 2012-2022 ($ BILLION) 15
CHAP 6. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY TYPES OF PLANT DRUGS, 2012-2022 ($ BILLION) 16
6.1. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY STEROIDS, 2012-2022 ($ BILLION) 16
6.2. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY PHENOLS, 2012-2022 ($ BILLION) 16
6.3. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY TERPENES, 2012-2022 ($ BILLION) 16
6.4. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY GLYCOSIDES, 2012-2022 ($ BILLION) 16
CHAP 7. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET, REGIONAL OUTLOOK 2012-2022 ($ BILLION) 17
7.1. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY REGION 2012-2022 ($ BILLION) 17
7.2. NORTH AMERICA 17
7.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 17
7.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 17
7.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 17
7.2.3.1. U.S. 17
7.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 17
7.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 17
7.2.3.2. CANADA 17
7.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 17
7.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 17
7.3. EUROPE 17
7.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 17
7.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 17
7.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 17
7.3.3.1. GERMANY 17
7.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 18
7.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 18
7.3.3.2. UK 18
7.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 18
7.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 18
7.3.3.3. FRANCE 18
7.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 18
7.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 18
7.3.3.4. ITALY 18
7.3.3.4.1. ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 18
7.3.3.4.2. ITALY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 18
7.3.3.5. REST OF EUROPE 18
7.3.3.5.1. RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 19
7.3.3.5.2. RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 19
7.3.3.5.3. OTHERS MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 19
7.3.3.5.4. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 19
7.4. ASIA PACIFIC 19
7.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 19
7.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 19
7.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 19
7.4.3.1. CHINA 19
7.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 19
7.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 19
7.4.3.2. INDIA 19
7.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 19
7.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 19
7.4.3.3. JAPAN 19
7.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 19
7.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 19
7.4.3.4. OTHERS 19
7.4.3.4.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($BILLION) 20
7.4.3.4.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 20
7.5. MIDDLE EAST & AFRICA 20
7.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 20
7.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 20
7.6. LATIN AMERICA 20
7.6.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 20
7.6.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 20
CHAP 8. COMPETITIVE LANDSCAPE 21
8.1. ABBOTT LABORATORIES 22
8.1.1. COMPANY OVERVIEW 22
8.1.2. SCOT ANALYSIS 22
8.1.3. PRODUCT BENCHMARKING 22
8.1.4. STRATEGIC INITIATIVES 22
8.2. BAYER HEALTHCARE 22
8.2.1. COMPANY OVERVIEW 22
8.2.2. SCOT ANALYSIS 22
8.2.3. PRODUCT BENCHMARKING 22
8.2.4. STRATEGIC INITIATIVES 22
8.3. BIONOVA 22
8.3.1. COMPANY OVERVIEW 22
8.3.2. SCOT ANALYSIS 22
8.3.3. PRODUCT BENCHMARKING 22
8.3.4. STRATEGIC INITIATIVES 22
8.4. BRISTOL MYERS 22
8.4.1. COMPANY OVERVIEW 22
8.4.2. SCOT ANALYSIS 22
8.4.3. PRODUCT BENCHMARKING 22
8.4.4. STRATEGIC INITIATIVES 22
8.5. ELI LILLY 22
8.5.1. COMPANY OVERVIEW 22
8.5.2. SCOT ANALYSIS 22
8.5.3. PRODUCT BENCHMARKING 22
8.5.4. STRATEGIC INITIATIVES 22
8.6. GLAXOSMITHKLINE 22
8.6.1. COMPANY OVERVIEW 22
8.6.2. SCOT ANALYSIS 23
8.6.3. PRODUCT BENCHMARKING 23
8.6.4. STRATEGIC INITIATIVES 23
8.7. JOHNSON & JOHNSON 23
8.7.1. COMPANY OVERVIEW 23
8.7.2. SCOT ANALYSIS 23
8.7.3. PRODUCT BENCHMARKING 23
8.7.4. STRATEGIC INITIATIVES 23
8.8. LUPIN LTD. 23
8.8.1. COMPANY OVERVIEW 23
8.8.2. SCOT ANALYSIS 23
8.8.3. PRODUCT BENCHMARKING 23
8.8.4. STRATEGIC INITIATIVES 23
8.9. MEDIGENE 23
8.9.1. COMPANY OVERVIEW 23
8.9.2. SCOT ANALYSIS 23
8.9.3. PRODUCT BENCHMARKING 23
8.9.4. STRATEGIC INITIATIVES 23
8.10. NOVARTIS INTERNATIONAL AG 23
8.10.1. COMPANY OVERVIEW 23
8.10.2. SCOT ANALYSIS 23
8.10.3. PRODUCT BENCHMARKING 23
8.10.4. STRATEGIC INITIATIVES 23
8.11. PFIZER 23
8.11.1. COMPANY OVERVIEW 23
8.11.2. SCOT ANALYSIS 23
8.11.3. PRODUCT BENCHMARKING 23
8.11.4. STRATEGIC INITIATIVES 23
8.12. RANBAXY LABORATORIES LTD. 24
8.12.1. COMPANY OVERVIEW 24
8.12.2. SCOT ANALYSIS 24
8.12.3. PRODUCT BENCHMARKING 24
8.12.4. STRATEGIC INITIATIVES 24
8.13. GLENMARK PHARMACEUTICALS LTD. 24
8.13.1. COMPANY OVERVIEW 24
8.13.2. SCOT ANALYSIS 24
8.13.3. PRODUCT BENCHMARKING 24
8.13.4. STRATEGIC INITIATIVES 24
8.14. TASLY PHARMACEUTICALS INC. 24
8.14.1. COMPANY OVERVIEW 24
8.14.2. SCOT ANALYSIS 24
8.14.3. PRODUCT BENCHMARKING 24
8.14.4. STRATEGIC INITIATIVES 24
8.15. PIRAMAL PHYTOCARE LTD. 24
8.15.1. COMPANY OVERVIEW 24
8.15.2. SCOT ANALYSIS 24
8.15.3. PRODUCT BENCHMARKING 24
8.15.4. STRATEGIC INITIATIVES 24
TABLE 1 GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY THERAPEUTIC APPLICATION, 2012-2022 ($ BILLION) 23
TABLE 2 GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY HORMONE DISEASES, 2012-2022 ($ BILLION) 23
TABLE 3 GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY INFECTIOUS DISEASES, 2012-2022 ($ BILLION) 23
TABLE 4 GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY PAIN AND CENTRAL NERVOUS SYSTEM DISORDERS, 2012-2022 ($ BILLION) 23
TABLE 5 GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY CARDIOVASCULAR AND METABOLIC DISEASES, 2012-2022 ($ BILLION) 23
TABLE 6 GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET BY RESPIRATORY AND ONCOLOGY DISEASES TREATMENT, 2012-2022 ($ BILLION) 23
TABLE 7 NORTH AMERICA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 23
TABLE 8 NORTH AMERICA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY REGION, 2012 – 2022 ($ BILLION) 23
TABLE 9 NORTH AMERICA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 23
TABLE 10 U.S. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 23
TABLE 11 U.S. GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 23
TABLE 12 CANADA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 23
TABLE 13 CANADA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 –2022 ($ BILLION) 23
TABLE 14 CANADA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 23
TABLE 15 MEXICO GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 24
TABLE 16 EUROPE GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 24
TABLE 17 EUROPE GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY REGION, 2012 – 2022 ($ BILLION) 24
TABLE 18 EUROPE GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 24
TABLE 19 GERMANY GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 24
TABLE 20 GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 24
TABLE 21 UK GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 24
TABLE 22 UK GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 24
TABLE 23 ASIA PACIFIC GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 24
TABLE 24 ASIA PACIFIC GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY REGION, 2012 – 2022 ($ BILLION) 24
TABLE 25 ASIA PACIFIC GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 24
TABLE 26 CHINA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 24
TABLE 27 CHINA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 24
TABLE 28 INDIA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 24
TABLE 29 INDIA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 24
TABLE 30 JAPAN GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 24
TABLE 31 JAPAN GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 24
TABLE 32 MIDDLE EAST & AFRICA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 25
TABLE 33 MIDDLE EAST & AFRICA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 25
TABLE 34 CENTRAL & SOUTH AMERICA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST, 2012 – 2022 ($ BILLION) 25
TABLE 35 CENTRAL & SOUTH AMERICA GLOBAL BOTANICAL AND PLANT DERIVED DRUGS MARKET ESTIMATES AND FORECAST BY APPLICATION, 2012 – 2022 ($ BILLION) 25
FIGURE 1 MARKET SHARE BY REGIONS 25
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
FIGURE 4 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
FIGURE 5 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
FIGURE 6 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
FIGURE 7 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
FIGURE 8 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
FIGURE 9 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
FIGURE 10 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
FIGURE 11 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
FIGURE 12 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
FIGURE 13 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)